Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334283 | 0.91 | ESR1 (0.56) | ESR2ESR1APPCYP2C19CYP2D6 | |
| SCHEMBL1335824 | 0.91 | ESR1 (0.50) | ESR2ESR1APPCYP2C19CYP2D6 | |
| SCHEMBL27974576 | 0.89 | ESR1 (0.57) | ESR2ESR1HSD11B1AKR1C1LMNA | |
| SCHEMBL350266 | 0.84 | APP (0.58) | ESR2ESR1APPCYP2C19CYP2D6 | |
| SCHEMBL518528 | 0.82 | ESR2 (0.45) | ESR2ESR1APPCYP2C19CYP2D6 | |
| SCHEMBL19264980 | 0.82 | ESR2 (0.45) | ESR2ESR1APPCYP2C19CYP2D6 | |
| SCHEMBL12120029 | 0.82 | ESR2 (0.45) | ESR2ESR1APPCYP2C19CYP2D6 | |
| SCHEMBL6618787 | 0.79 | HDAC1 (0.44) | HSD11B1AKR1C1MAPTCA1CA2 | |
| SCHEMBL2321735 | 0.79 | HSD11B1 (0.59) | HSD11B1LMNAHTTKDM4EALDH1A1 | |
| SCHEMBL3970990 | 0.79 | HSD11B1 (0.49) | APPCYP2C19CYP2C9CYP3A4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| EP-2000462-A2 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2008-12-10 | — | — | EP | disclosed |
| US-7169928-B2 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SOCIETE CIVILE BIOPROJECT (FR) | 2007-01-30 | — | — | US | disclosed |
| US-7138413-B1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SOCIETE CIVILE BIOPROJET (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | disclosed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1428820-A1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2004-06-16 | — | — | EP | disclosed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | ESR2 1694/4885ESR1 946/4885APP 118/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | ESR2 1122/4885ESR1 1329/4885APP 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.